A detailed history of Northern Trust Corp transactions in Gritstone Bio, Inc. stock. As of the latest transaction made, Northern Trust Corp holds 730,879 shares of GRTS stock, worth $445,836. This represents 0.0% of its overall portfolio holdings.

Number of Shares
730,879
Previous 754,463 3.13%
Holding current value
$445,836
Previous $1.94 Million 76.63%
% of portfolio
0.0%
Previous 0.0%

Shares

23 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$0.62 - $2.35 $14,622 - $55,422
-23,584 Reduced 3.13%
730,879 $453,000
Q1 2024

May 14, 2024

BUY
$1.96 - $2.9 $44,180 - $65,368
22,541 Added 3.08%
754,463 $1.94 Million
Q4 2023

Feb 13, 2024

BUY
$1.28 - $2.85 $11,261 - $25,074
8,798 Added 1.22%
731,922 $1.49 Million
Q3 2023

Nov 13, 2023

BUY
$1.19 - $2.26 $15,023 - $28,532
12,625 Added 1.78%
723,124 $1.24 Million
Q2 2023

Aug 11, 2023

BUY
$1.66 - $3.03 $926,178 - $1.69 Million
557,939 Added 365.72%
710,499 $1.39 Million
Q1 2023

May 15, 2023

BUY
$2.13 - $3.74 $8,285 - $14,548
3,890 Added 2.62%
152,560 $424,000
Q4 2022

Feb 13, 2023

BUY
$2.17 - $3.92 $55,009 - $99,372
25,350 Added 20.56%
148,670 $512,000
Q3 2022

Nov 14, 2022

BUY
$2.46 - $4.75 $19,778 - $38,190
8,040 Added 6.97%
123,320 $317,000
Q2 2022

Aug 12, 2022

SELL
$1.77 - $4.34 $497,488 - $1.22 Million
-281,067 Reduced 70.91%
115,280 $279,000
Q1 2022

May 13, 2022

SELL
$4.03 - $12.19 $50,612 - $153,094
-12,559 Reduced 3.07%
396,347 $1.63 Million
Q4 2021

Feb 08, 2022

BUY
$8.76 - $13.71 $346,046 - $541,586
39,503 Added 10.69%
408,906 $5.26 Million
Q3 2021

Nov 15, 2021

SELL
$6.41 - $13.54 $865,555 - $1.83 Million
-135,032 Reduced 26.77%
369,403 $3.99 Million
Q2 2021

Aug 13, 2021

BUY
$8.13 - $10.2 $1.8 Million - $2.26 Million
221,789 Added 78.47%
504,435 $4.61 Million
Q1 2021

May 12, 2021

SELL
$4.07 - $27.11 $66,369 - $442,082
-16,307 Reduced 5.45%
282,646 $2.67 Million
Q4 2020

Feb 11, 2021

SELL
$2.57 - $4.22 $47,185 - $77,479
-18,360 Reduced 5.79%
298,953 $1.18 Million
Q3 2020

Nov 16, 2020

SELL
$2.63 - $8.09 $55,729 - $171,427
-21,190 Reduced 6.26%
317,313 $841,000
Q2 2020

Aug 14, 2020

BUY
$5.69 - $8.17 $276,818 - $397,470
48,650 Added 16.78%
338,503 $2.25 Million
Q1 2020

May 14, 2020

BUY
$5.47 - $11.3 $56,133 - $115,960
10,262 Added 3.67%
289,853 $1.69 Million
Q4 2019

Feb 14, 2020

BUY
$7.07 - $11.61 $66,648 - $109,447
9,427 Added 3.49%
279,591 $2.51 Million
Q3 2019

Nov 13, 2019

BUY
$8.45 - $12.28 $1.31 Million - $1.9 Million
154,769 Added 134.12%
270,164 $2.33 Million
Q2 2019

Aug 13, 2019

BUY
$9.2 - $15.7 $341,494 - $582,768
37,119 Added 47.42%
115,395 $1.29 Million
Q1 2019

May 13, 2019

BUY
$9.97 - $18.96 $1,684 - $3,204
169 Added 0.22%
78,276 $1.04 Million
Q4 2018

Feb 12, 2019

BUY
$11.61 - $31.1 $906,822 - $2.43 Million
78,107 New
78,107 $1.21 Million

Others Institutions Holding GRTS

About Gritstone bio, Inc.


  • Ticker GRTS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 73,006,896
  • Market Cap $44.5M
  • Description
  • Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies against multiple cancer types and infectious diseases. Its lead product candidate is GRANITE, a neoantigen-based immunotherapy for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder ...
More about GRTS
Track This Portfolio

Track Northern Trust Corp Portfolio

Follow Northern Trust Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.